Amyotrophic Lateral Sclerosis Market Report and Forecast 2025-2034

Amyotrophic Lateral Sclerosis Market Outlook

The amyotrophic lateral sclerosis market size was valued at USD 716.3 million in 2024, driven by the increasing incidence of amyotrophic lateral sclerosis across the globe. The market is expected to grow at a CAGR of 5.5% during the forecast period of 2025-2034, with the values likely to rise from USD 755.6 million in 2025 to USD 1159.1 million by 2034.

Amyotrophic Lateral Sclerosis: Introduction

Amyotrophic lateral sclerosis (ALS) is a motor neuron disease that causes loss of muscle control. It begins with muscle weakness and twitching in the arms or legs, muscle cramps, spasms, difficulty swallowing, slurred speech. In rare cases, patients may also experience trouble with decision making or develop a form of dementia. ALS causes motor neurons to deteriorate and die. Motor neurons extend from the brain to spinal cord and are responsible for voluntary muscle movements such as walking and talking.

There is no single test for ALS diagnosis. It is identified through a series of neurological exams that analyze reflexes, muscle strength and other responses.

Amyotrophic Lateral Sclerosis Market Analysis

ALS is a fatal disease projected to affect approximately 376,674  people by 2040. The current ALS treatments include oral medications like Radicava ORS® (edaravone) and combination therapies like AMX0035, which comprises two medications sodium phenylbutyrate and tauroursodeoxycholic acid, have been commonly used as a treatment method. However, with increasing medical advances and high amyotrophic lateral sclerosis market demand, novel treatment methods have surfaced the market.

Relyvrio (sodium phenylbutyrate/taurursodiol) is one of the most recent oral medications approved by the US Food and Drug Administration (FDA). Northwestern University scientists have been working on a new experimental drug called NU-9. As per scientists, this drug has an advanced effect when given in combination to riluzole and edaravone (other ALS treatment drugs). Stem cell therapies and gene therapies are also a key area of interest among researchers, set to aid the amyotrophic lateral sclerosis market growth in the upcoming years.

In April 2023, FDA granted an accelerated approval for QALSODY™ (tofersen), the first treatment to target the genetic cause of ALS. It was developed in a Biogen and Ionis Pharmaceutical collaboration to specifically target the RNA produced by SOD1 gene, present in affected patients. Other ALS related genes including C9orf72, TBK1, and NEK1, are also under investigation for creating potential and effective drugs for patients.

Amyotrophic Lateral Sclerosis Market Segmentation

Market Breakup by Type

• Sporadic ALS

• Familial ALS

Market Breakup by Treatment Type

• Chemotherapy

• Stem Cell Therapy

• Physical Therapy 

• Others

Market Breakup by Diagnosis Method

• Electromyogram

• MRI

• Blood and Urine Tests

• Spinal Tap

• Muscle Biopsy

• Others

Market Breakup by End User

• Hospitals and Clinics

• Cancer Research Centres

• Others

Market Breakup by Distribution Channels

• Hospital Pharmacy

• Retail Pharmacy

• Online Pharmacy

• Others

Market Breakup by Region

• United States

• EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom

• Japan

Amyotrophic Lateral Sclerosis Market Overview

North America has led the global market owing to the presence of a well-equipped research and healthcare infrastructure. The United States being an innovative hub with several healthcare giants also fuels the market size. Understanding the seriousness of the disease, unique initiatives like the Ice Bucket Challenge have been adding significant value to spread awareness as well as raising funds for treatment developments. The ALS Ice Bucket Challenge went viral and raises approximately USD 2.2 million, which have been submitted for funding the development and trial for new ALS drug.

Europe, with comparatively higher ALS incidence (2.6 per 100,000), is expected to lead the global market, given the premium healthcare benefits provided by the government. The Asia Pacific amyotrophic lateral sclerosis market is projected to witness exponential growth. The rising geriatric population is fuelling several technical advancements in the healthcare sector to facilitate the best resources to the patients. Moreover, the region has also been experiencing a massive influx of foreign investments, which can be attributed to the easy availability and affordability of resources.

Amyotrophic Lateral Sclerosis Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Orion Corporation

• Bausch Health Companies Inc.

• CYTOKINETICS, INC.

• Aquestive Therapeutics, Inc.

• Sanofi

• Covis Pharma

• Sun Pharmaceuticals Industries Ltd

• Mitsubishi Tanabe Pharma Corporation

• BrainStorm Cell Limited

• ViroMed Co., Ltd

• Ionis Pharmaceuticals

• Genervon Biopharmaceuticals, LLC

• Biogen

• Orphazyme A/S

• F. Hoffmann-La Roche Ltd

Key Highlights of the Report